Pasar al contenido principal

DESCUBRIMIENTO DE ANTIVIRALES DE AMPLIO ESPECTRO BASADOS EN QUINASAS QUE ACTUAN SOBRE LA ENTRADA VIRAL

PID2021-122223OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discovery of thiophene derivatives as potent, orally bioavailable, and blood–brain barrier-permeable Ebola virus entry inhibitors

  • Morales-Tenorio, Marcos
  • Lasala, Fátima
  • García-Rubia, Alfonso
  • Aledavood, Elnaz
  • Heung, Michelle
  • Olal, Catherine
  • Escudero-Pérez, Beatriz
  • Alonso Martí, Covadonga
  • Martínez Gil, Ana
  • Muñoz-Fontela, César
  • Delgado, Rafael
  • Gil, Carmen
22 p.-7 fig.-7 tab.-5 schem.-1 graph. abst., The endemic nature of the Ebola virus disease in Africa underscores the need for prophylactic and therapeutic drugs that are affordable and easy to administer. Through a phenotypic screening employing viral pseudotypes and our in-house chemical library, we identified a promising hit featuring a thiophene scaffold, exhibiting antiviral activity in the micromolar range. Following up on this thiophene hit, a new series of compounds that retain the five-membered heterocyclic scaffold while modifying several substituents was synthesized. Initial screening using a pseudotype viral system and validation assays employing authentic Ebola virus demonstrated the potential of this new chemical class as viral entry inhibitors. Subsequent investigations elucidated the mechanism of action through site-directed mutagenesis. Furthermore, we conducted studies to assess the pharmacokinetic profile of selected compounds to confirm its pharmacological and therapeutic potential., The project leading to these results has received funding from “la Caixa” Foundation under the project code LCF/PR/HR19/52160012. This research was partially supported through ERA-NET-2021-862605. Cofounded by AEI, Spain (PCI2021-121939 (C.A.), PID2021-122825OB (C.A.), and PID2021-122223OB-I00 (C.G.)), Instituto de Salud Carlos III (CIBERINFEC, CIBERNED, and FIS PI2100989), and the European Commission Horizon 2020 Framework Programme (Project VIRUSCAN FETPROACT-2016: 731868 and Project EPIC-CROWN-2 ID: 101046084). This research work was also funded by the European Commission–NextGenerationEU (Regulation EU 2020/2094) through CSIC’s Global Health Platform (PTI Salud Global). M.M.-T. holds a predoctoral FPU grant (FPU18/03493) from MICINN., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

From diarylsulfides to diarylamines: new Ebola virus entry inhibitors with improved metabolic stability

  • Morales-Tenorio, Marcos
  • Lasala, Fátima
  • García-Rubia, Alfonso
  • Aledavood, Elnaz
  • Heung, Michelle
  • Olal, Catherine
  • Escudero-Pérez, Beatriz
  • Oquist, Paola
  • Canales, Ángeles
  • Alonso Martí, Covadonga
  • Martínez Gil, Ana
  • Muñoz-Fontela, César
  • Delgado, Rafael
  • Gil, Carmen
15 p.-7 fig.-4 tab.-1 graph. abst., The persistence of current outbreaks of Ebola virus (EBOV) disease and challenges in the production and administration of approved vaccines and treatments highlight the continuous exploration of new therapeutic alternatives. In this context, this work focuses on optimizing diarylsulfide hits previously identified as EBOV entry inhibitors. Structural modifications resulted in diarylamine derivatives, with confirmed antiviral activity against replicative EBOV and significantly improved metabolic stability compared to diarylsulfides. Using different techniques, the EBOV glycoprotein (EBOV-GP) was identified as the target of these compounds. Residue Y517GP2 is critical for biological activity, while T519GP2, E100GP1, and D522GP2 also contribute to ligand binding. Furthermore, the binding of the derivatives to EBOV-GP has been shown to destabilize the complex with the virus receptor NPC1. In short, a new family of diarylsulfides and diarylamines with antiviral activity against EBOV has been developed, and their mechanism of action has been deciphered, paving the way for future pharmaceutical development., The project leading to these results has received funding from “la Caixa” Foundation under the project code LCF/PR/HR19/52160012. This research was partially supported through ERA-NET-2021-862605 and cofounded by MICIU/AEI/10.13039/501100011033 and FEDER/UE (Grants PCI2021-121939 (C.A.), PID2021-122825OB (C.A.), PID2023-151109OB-I00 (A.C.) and PID2021-122223OB-I00 (C.G.)), Instituto de Salud Carlos III (CIBERINFEC, CIBERNED and FIS PI2100989), and the European Commission Project e-FabRIC: ID: 101137157, HORIZON-HLTH-2023-DISEASE-03-04 and Project Ebola PREP-TBOX, ID 101145709, and HORIZON-JU-GH-EDCTP3-2023-01 to RD. This research work was also funded by the European Commission–NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI+ Salud Global). M.M.-T. holds a predoctoral FPU grant (FPU18/03493) from MICINN., Peer reviewed